MAPK9: A Protein Involved in Cell Signaling and Disease (G4293)

Target Name: MAP3K9

NCBI ID: G4293

MAP3K9

MAPK9: A Protein Involved in Cell Signaling and Disease

MAP3K9 (MLK1) is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the MAPK/ERK signaling pathway, which is a well-established pathway for cell signaling that plays a crucial role in the regulation of cellular processes such as cell growth, differentiation, and survival.

MAP3K9 is involved in a wide range of cellular processes, including the regulation of inflammation, cell migration, and the establishment of cellular tissues and organs. It is also involved in the regulation of pain perception and neurodegenerative diseases.

Despite its importance, MAP3K9 is not well understood, and its functions and interactions with other proteins and molecules are not well defined. It is also a drug target that can be potential target for new therapies.

The MAPK/ERK signaling pathway is a complex signaling pathway that is involved in the regulation of cellular processes that are essential for life. The pathway is composed of several proteins, including MAPK4 (also known as ERK1/2), MAPK8 (also known as ERK3), and MAPK9 (also known as MLK1).

MAPK9 is a 21-kDa protein that is expressed in various tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is a key component of the MAPK/ERK signaling pathway and is involved in the regulation of cellular processes that are essential for life.

MAPK9 is involved in the regulation of cell growth and differentiation. It plays a role in the regulation of cell proliferation, cell migration, and the formation of tissues and organs. It is also involved in the regulation of cell survival and the establishment of cellular tissues and organs.

MAPK9 is involved in the regulation of inflammation. It is involved in the regulation of the immune response and the regulation of inflammation. It is also involved in the regulation of pain perception and the regulation of neurodegenerative diseases.

MAPK9 is a drug target. It is a potential target for new therapies that can be used to treat a wide range of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

In conclusion, MAP3K9 (MLK1) is a protein that is involved in the regulation of cellular processes that are essential for life. It is a key component of the MAPK/ERK signaling pathway and is involved in the regulation of cell growth, differentiation, inflammation, and pain perception. As a drug target, MAPK9 is a promising target for new therapies that can be used to treat a wide range of diseases.

Protein Name: Mitogen-activated Protein Kinase Kinase Kinase 9

Functions: Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. Plays an important role in the cascades of cellular responses evoked by changes in the environment. Once activated, acts as an upstream activator of the MKK/JNK signal transduction cascade through the phosphorylation of MAP2K4/MKK4 and MAP2K7/MKK7 which in turn activate the JNKs. The MKK/JNK signaling pathway regulates stress response via activator protein-1 (JUN) and GATA4 transcription factors. Also plays a role in mitochondrial death signaling pathway, including the release cytochrome c, leading to apoptosis

The "MAP3K9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAP3K9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets